Progressed MM patients were frequently treated with anti-CD38 mAb (daratumumab, as mono or part of double or triple therapy) or proteasome inhibitors (carfilzomib and/or bortezomib) (Table 2). This evidence concerns the gene CD38 and Miyoshi myopathy.